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What prompted your interest in microbiology, 
specifically the role of Helicobacter pylori 
in stomach infections, gastric and duodenal 
ulcers, and stomach cancer?
This fascinating organism was only discovered in 
the 1980s, by the Nobel prize-winning Australian 
researchers Barry Marshall and Robin Warren. 
They found that H. pylori was virtually always 
present in the stomach of people suffering 
from ulcers, and they were the first to isolate it. 
Famously, Marshall even infected himself with 
the organism to prove that it caused gastric 
inflammation. Aside from its fascinating history, 
the bacterium has adapted in many sophisticated 
ways so that it can remain (usually silently) in its 
host for many decades: it is equipped to survive 
in the harsh acidic conditions of the stomach 
and is able to avoid being cleared by the immune 
system. This pathogen has a multitude of very 
intriguing features.
What is human ơ-defensin 1 (hơD1)? How 
does H. pylori interfere with its expression, 
and why is this interaction important to 
human health?
HơD1 is an antimicrobial peptide produced at 
epithelial surfaces – such as the eye, respiratory 
tract, and gut and genital tract – to defend 
surfaces of the body against infections. In a 
recent paper, we showed that H. pylori is able to 
act on epithelial cells overlying the stomach lining 
to make them reduce their production of hơD1. 
This effect was even more apparent in patients 
infected with virulent strains that are positive 
for the cag pathogenicity island (cagPAI). The 
cagPAI encodes a type IV secretion system, which 
acts like a molecular syringe to inject bacterial 
components into human cells. Strains expressing 
this secretion system are more likely to cause 
gastric cancer than those that do not, but the 
relationship is not completely understood.
In what manner can H. pylori induce changes 





s are more abundant in the gastric mucosa 
and peripheral blood of infected patients 
compared to uninfected controls. These cells 
secrete cytokines, which suppress inflammation 
and promote immunosuppression. We proposed 
that such cells could also inhibit damaging 
responses at sites outside the gastric mucosa. We 
therefore wished to understand more about this 
response, how it is generated and what drives 
these immunosuppressive cells to accumulate in 
the gastric mucosa.
You currently collaborate with the Nottingham 
Digestive Diseases Biomedical Research Unit 
and the Department of Pathology at the 
University of Nottingham. How have these 
partnerships facilitated the study?
We use a variety of approaches in our lab, and 
we believe it is of paramount importance to 
understand what is happening in the stomachs 
of infected people before going on to perform 
experiments with in vitro or in vivo models. 
Because our research is patient-focused, we 
know that our findings are directly relevant. 
They provide more information on how 
the bacteria interact with the cells of the 
stomach lining, and better inform us about 
disease mechanisms. We are fortunate to be 
a part of the National Institute for Health 
Research-funded Nottingham Digestive 
Diseases Biomedical Research Unit, as its aim 
is to facilitate patient-based and translational 
research in gastroenterology. The facilities 
and the staff that are employed in this centre 
are absolutely key to our research. We are 
extremely grateful to the patients attending the 
Queen’s Medical Centre in Nottingham who 
donate samples of blood and gastric biopsies for 
our research.
Microbiology is an ever-evolving discipline. 
Where do you see it heading?
Technological advances, such as those in 
gene sequencing, have revolutionised our 
discipline. I am constantly amazed by the new 
data characterising microbial gut flora and the 
diverse effects this has on health and disease. 
It is incredible that the mixture of microbes in 
our gastrointestinal tract can have such a strong 
influence on conditions outside the gut, such as 
obesity, diabetes, multiple sclerosis, the ageing 
processes and even our behaviour. I recently 
helped organise a symposium for the Society 
for General Microbiology Annual Conference on 
mind-altering microbes, where speakers showed 
that organisms in our gut have a major impact 
on depression, anxiety and even Parkinson’s 
disease. In the future, I envisage that people will 
be able to manipulate their gut flora, perhaps 
with probiotics, to become healthier, happier 
and thinner.
Microbiological expert Dr Karen 
Robinson discusses the future of the 
field, and shares insights into her 
work on a highly prevalent strain of 
gastrointestinal bacteria that infects 
















Electron micrograph of negatively stained H. pylori bacteria.
SINCE ITS DISCOVERY around 30 years ago, 
Helicobacter pylori has been identified as one 
of the most common bacterial infections in 
the world. H. pylori infects the gastric mucosa 
of humans, and it is highly developed for this 
purpose; its body, only around 4 µm long, is a 
helix-shaped rod with a set of beating flagella 
that endows it with great manoeuvrability. 
Burrowing into the mucus lining of the 
stomach, these bacteria express virulence 
factors that affect host cells and allow them to 
gain a degree of control over their environment. 
In most cases, people infected with H. pylori 
remain asymptomatic, and the bacterium 
usually goes undetected. 
Because of this, the bacterium has been 
able to infect more than half of the world’s 
population: most people are simply unaware 
they are infected. In some cases, however, this 
diminutive organism can cause pronounced 
problems. Between 10 and 15 per cent of those 
infected will suffer from ulcers in the stomach 
or duodenum, and in as many as 2 per cent of 
cases, the result will be gastric cancer. Around 
a million people every year are diagnosed with 
stomach cancer, the second-leading cause 
of cancer-related mortality globally, and 
60 per cent of these cases are thought to be 
attributable to H. pylori infection. In the UK 
alone, medical professionals diagnose 7,000 
gastric cancer cases each year, but even with 
a high standard of healthcare, the five-year 
survival rate is set at a discouraging 15 per cent. 
TIMING IS EVERYTHING
The problem with stomach cancer arising 
from H. pylori – as with many of the most 
deadly cancers – is with diagnosis. Because the 
bacterial infection is largely asymptomatic and 
gastric tumours themselves do not produce 
observable problems until they are relatively 
advanced, this form of cancer is difficult to 
recognise before it becomes life threatening. 
By achieving a more complete understanding 
of the interaction between Helicobacter and 
the human body, it may be possible for medical 
professionals to identify the people the disease 
is likely to affect earlier. Further, this knowledge 
could uncover ways to improve the efficiencies 
of current antibiotic therapies for eradicating 
the infection.
Dr Karen Robinson at the University of 
Nottingham’s Digestive Diseases Centre, UK, 
together with Professor John Atherton, leads 
one research group dedicated to pursuing this 
valuable information. Using approaches from 
clinical investigations to longitudinal birth 
cohort studies, the researchers have revealed 
a wealth of information about the deleterious 
microorganism and its interaction with the 
body of its host. Most of these discoveries 
have related to the progression of infection 
towards disease. 
MOLECULAR AMELIORATION
One area the Nottingham scientists have been 
particularly interested in is the mechanism 
the bacteria use to suppress the production of 
human ơ-defensin 1 (hơD1), a protective anti-
microbial peptide that human cells express. 
Using a cell culture model, they showed 
that the cag type IV secretion system, which 
certain strains of H. pylori employ, activates 
signalling pathways in human gastric epithelial 
cells that suppress the production of hơD1. 
This is a surprising result, since the same 
pathways are also involved in the generation 
of an inflammatory response in the tissue. This 
mechanism allows the bacteria to alter their 
environment to suit their needs, but over time, 
this causes damage to the affected tissue.
Using samples collected from patients at 
Queen’s Medical Centre in Nottingham, the 
microbiologists subsequently discovered that 
people infected with cag-positive bacteria 
had reduced hơD1 levels and therefore larger 
populations of bacteria surviving in their 
stomachs. With continued study, they have 
found methods for identifying the bacterial 
strains capable of manipulating the human 
system in this way. Since their research is 
patient-focused, Robinson and her collaborators 
feel more certain that their findings will be 
directly relevant to clinical practice, while 
informing the scientific understanding of the 
mechanisms behind the disease.
UNLIKELY ALLIES
Robinson and her colleagues have also 
investigated some protective consequences 
of infection with H. pylori, which are equally 
fascinating. A particular interest is how 
the infection stimulates a cell type called 
regulatory T cells, which dampen inflammation 
and suppress damaging immune responses, 
such as in asthma. In a recent paper, Robinson’s 
group demonstrated that most regulatory 
T cells in the human gastric mucosa express 
a certain chemokine receptor. This receptor, 
CCR6, attracts cells towards its ligand, CCL20, 
which appears in areas of the mucosa with H. 
pylori. Infected patients had larger populations 
of regulatory T cells in their peripheral blood, 
and a higher proportion of them expressed 
CCR6 – indicating, that they might have a more 
robust and flexible immune system than those 
who have never been affected.
This impact of infection may seem 
counterintuitive, but in a wider context, it 
makes perfect sense. For at least 50,000 
years, humans have been coevolving with H. 
pylori – and with more than half of the world’s 
population still hosting bacterial populations 
today, infection is arguably the ancestral state 
of humans. In other words, the modern human 
immune system is designed with the presence 
of bacteria in mind, and its absence may be 
at the root of the allergies and autoimmune 
conditions that are exploding in developed 
countries today. In 1989, immunologist David 
Strachan was among the first to identify 
this possibility, referring to it as ‘the hygiene 
hypothesis’. Since then, scientists have 
identified early exposure to many infectious 
diseases, including various gastrointestinal 
parasites and soil mycobacteria, as a possible 
stimulator of a healthy immune system.
TURNING THE TIDE
Is H. pylori among these unlikely medical 
helpers? The investigations going on in 
Nottingham suggest it is possible. The 
prevalence of infection with this bacterium has 
dramatically declined in developed countries, 
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while the incidence of asthma and allergies 
has risen exponentially – and the data from 
Robinson’s team suggest that the differences 
in regulatory T cell populations that H. pylori 
produce are behind this shift. Past studies of 
the relationship between bacterial infection 
and allergy, however, have been almost 
universally cross-sectional – which is not 
ideal for examining a medical phenomenon 
that seems to have a profound impact on 
disease development.
In light of this, the Nottingham researchers 
joined in a longitudinal birth cohort study to 
investigate claims of a protective association 
between infection and childhood asthma. 
The research focused on the Butarija Birth 
Cohort in rural Ethiopia, and drew on data 
collected at four points in the children’s 
lives. The results were striking. The study 
searched for associations between H. pylori, 
intestinal parasites or intestinal microflora 
and the risk of wheeze, eczema, hay fever 
and allergic skin sensitisation in 878 children 
at ages three and five. The researchers only 
found statistically significant protective 
associations present with H. pylori.
GOING FORWARD
Building on this intriguing work, Robinson 
and her team will now begin to investigate 
these relationships in a more mechanistic 
way. In order to do this, they plan to work 
closely with tissue engineers to create an 
in vitro multicellular model of the human 
gastric mucosa, a physiological model that 
might yield further information on the 
interaction between immune, stromal and 
epithelial cells during bacterial infection. 
Through ambitious endeavours such as 
this, the lab will likely retain the position 
it currently holds as a leading research 
institution in this area.
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